hVIVO PLC
LSE:HVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
hVIVO PLC
Other Liabilities
hVIVO PLC
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
hVIVO PLC
LSE:HVO
|
Other Liabilities
£2.5m
|
CAGR 3-Years
57%
|
CAGR 5-Years
164%
|
CAGR 10-Years
N/A
|
|
|
Oxford Biodynamics PLC
LSE:OBD
|
Other Liabilities
£532k
|
CAGR 3-Years
8%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Other Liabilities
£4.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Other Liabilities
£91k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Other Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Other Liabilities
£31k
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
hVIVO PLC
Glance View
hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
See Also
What is hVIVO PLC's Other Liabilities?
Other Liabilities
2.5m
GBP
Based on the financial report for Dec 31, 2025, hVIVO PLC's Other Liabilities amounts to 2.5m GBP.
What is hVIVO PLC's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
164%
Over the last year, the Other Liabilities growth was 33%. The average annual Other Liabilities growth rates for hVIVO PLC have been 57% over the past three years , 164% over the past five years .
